Aripiprazole lauroxil - Generic Drug Details

What are the generic drug sources for aripiprazole lauroxil and what is the scope of freedom to operate?

Aripiprazole lauroxil is the generic ingredient in two branded drugs marketed by Alkermes Inc and is included in two NDAs. There are twenty patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Aripiprazole lauroxil has one hundred and ninety-four patent family members in twenty-nine countries.

There are three drug master file entries for aripiprazole lauroxil. One supplier is listed for this compound.

Summary for aripiprazole lauroxil

International Patents:	194
US Patents:	20
Tradenames:	2
Applicants:	1
NDAs:	2
Drug Master File Entries:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	38
Clinical Trials:	7
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for aripiprazole lauroxil
What excipients (inactive ingredients) are in aripiprazole lauroxil?	aripiprazole lauroxil excipients list
DailyMed Link:	aripiprazole lauroxil at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for aripiprazole lauroxil

Dosage:

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Dosage:

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for aripiprazole lauroxil

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Miami	Phase 4
University of California, Los Angeles	Phase 4
Alkermes, Inc.	Phase 4

See all aripiprazole lauroxil clinical trials

Pharmacology for aripiprazole lauroxil

Drug Class

Atypical Antipsychotic

Anatomical Therapeutic Chemical (ATC) Classes for aripiprazole lauroxil

N05AX	Other antipsychotics
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

US Patents and Regulatory Information for aripiprazole lauroxil

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-003	Oct 5, 2015		RX	Yes	Yes				Y
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-002	Oct 5, 2015		RX	Yes	No			Y
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-004	Jun 5, 2017		RX	Yes	No
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-004	Jun 5, 2017		RX	Yes	No
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-002	Oct 5, 2015		RX	Yes	No			Y
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-003	Oct 5, 2015		RX	Yes	Yes

International Patents for aripiprazole lauroxil

Country	Patent Number	Title	Estimated Expiration
Poland	3182958
European Patent Office	3156056
Croatia	P20171415
Japan	2012531434
Australia	2013349388	Pharmaceutical compositions having improved storage stability
Serbia	55434

Supplementary Protection Certificates for aripiprazole lauroxil

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1675573	C300669	Netherlands		PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115
1675573	300669	Netherlands		PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115
1675573	2014C/029	Belgium		PRODUCT NAME: ARIPIPRAZOLE; AUTHORISATION NUMBER AND DATE: EU/1/13/882 20131119
1675573	92427	Luxembourg		PRODUCT NAME: ARIPIPRAZOLE
0367141	SPC/GB04/039	United Kingdom		PRODUCT NAME: ARIPIPRAZOLE OR A SALT THEREOF; REGISTERED: UK EU/1/04/276/001 20040604; UK EU/1/04/276/002 20040604; UK EU/1/04/276/003 20040604; UK EU/1/04/276/004 20040604; UK EU/1/04/276/005 20040604; UK EU/1/04/276/006 20040604; UK EU/1/04/276/007 20040604; UK EU/1/04/276/008 20040604; UK EU/1/04/276/009 20040604; UK EU/1/04/276/010 20040604; UK EU/1/04/276/011 20040604; UK EU/1/04/276/012 20040604; UK EU/1/04/276/013 20040604; UK EU/1/04/276/014 20040604; UK EU/1/04/276/015 20040604; UK EU/1/04/276/016 20040604; UK EU/1/04/276/017 20040604; UK EU/1/04/276/018 20040604; UK EU/1/04/276/019 20040604; UK EU/1/04/276/020 20040604

Market Dynamics and Financial Trajectory for Aripiprazole Lauroxil

Last updated: March 5, 2026

What is Aripiprazole Lauroxil?

Aripiprazole Lauroxil is an extended-release injectable formulation of aripiprazole, approved by the U.S. Food and Drug Administration (FDA) in January 2017. It is designed for once-monthly administration for the treatment of schizophrenia in adult patients. The drug facilitates long-acting pharmacokinetics, improving adherence compared to oral aripiprazole. Its under-the-skin (intramuscular) formulation influences pricing, market share, and competitive dynamics.

How does Aripiprazole Lauroxil fit within the antipsychotic market?

Aripiprazole Lauroxil competes primarily with other long-acting injectable (LAI) antipsychotics, including:

• Risperdal Consta (risperidone)
• Paliperidone Palmitate (Invega Sustenna)
• Olanzapine pamoate (Zyprexa Relprevv)
• Haloperidol decanoate

Market share depends on drug efficacy, administration frequency, side-effect profile, and physician familiarity. The long-acting injectables (LAIs) target medication adherence issues and reduce relapse risks in schizophrenia, a condition affecting over 20 million globally.

What are the current sales figures and revenue estimates?

While comprehensive, up-to-date global sales data are limited, the following are estimates:

• U.S. launch (2017) initially generated approximately $50 million in revenue during the first year.
• By 2020, sales in the U.S. increased to about $240 million, according to IQVIA.
• Total global sales are not publicly disclosed but are expected to remain predominantly U.S.-centered due to approval status and reimbursement factors.

The first quarter of 2023 reported U.S. sales of approximately $60 million, representing steady growth driven by increased provider adoption.

What factors influence the financial trajectory?

Market Penetration and Adoption Rates

The drug's uptake depends on prescriber familiarity and perceived benefits over oral formulations and competing LAIs. The introduction of biosimilars, patient preferences, and insurance coverage policies impact sales.

Pricing Strategy

Aripiprazole Lauroxil is priced at a slight premium relative to oral aripiprazole but remains competitive with other LAIs. Approximate list prices are:

• $1,200 to $1,400 per injection pill
• Equivalent to roughly $14,400 to $16,800 annually per patient, assuming once-monthly dosing

Reimbursement negotiations with payers influence net revenue.

Competition and Market Share

Despite being a latecomer compared to risperidone LAI (marketed since 2003), Aripiprazole Lauroxil benefits from a favorable side-effect profile, particularly lower weight gain and metabolic side effects. Competitors like Risperdal Consta have higher market share, but the newer agent gains ground in patient acceptance.

Regulatory and Reimbursement Environment

Changes in regulatory policies, formulary placements, and adoption of value-based reimbursement directly impact revenue. Expanded indications, such as maintenance therapy in bipolar disorder, could further bolster sales.

Patent and Exclusivity Periods

The drug's patent protection extends until at least 2030, with potential exclusivity periods due to data protections. Patent challenges in the U.S. could influence generic development and pricing in the long-term.

How will market trends influence the financial outlook?

Growing Prevalence of Schizophrenia

Global schizophrenia prevalence is stable, but increased awareness and diagnosis contribute to ongoing demand, especially in North American and European markets.

Treatment Guidelines

The American Psychiatric Association recommends LAI formulations for patients with adherence issues, expanding the patient population eligible for Aripiprazole Lauroxil.

Healthcare Policy Shifts

Policies favoring medications that improve adherence and reduce hospitalization rates positively influence long-term market expansion.

Biologics and Biosimilar Competition

While biosimilars are more common in biologic drugs, biosimilar competition could emerge for injectable antipsychotics, potentially exerting downward pressure on prices.

What is the projected revenue growth?

Analysts forecast:

Year	Estimated Global Revenue	CAGR (2022-2027)
2022	$250 million	—
2023	$275 million	10%
2024	$300 million	9%
2025	$330 million	10%
2026	$365 million	11%
2027	$405 million	11%

Growth driven by increased market penetration, expanding indications, and healthcare system adoption.

What risks threaten long-term viability?

• Patent challenges could introduce generics earlier.
• Competition from new molecular entities or formulations.
• Changes in prescribing practices or reimbursement policies.
• Off-label use limitations.

Key Takeaways

• Aripiprazole Lauroxil has experienced steady growth since its 2017 U.S. approval, with revenue estimates around $250 million globally in 2022.
• Factors such as market penetration, competitive positioning, and reimbursement policies influence its financial trajectory.
• Revenue projections suggest a compound annual growth rate of approximately 10-11% through 2027.
• Competition, patent timelines, and policy shifts pose risks to long-term market share.

FAQs

1. How does Aripiprazole Lauroxil compare cost-wise to oral aripiprazole?
The annual cost for the injectable is roughly $14,400–$16,800 per patient, higher than oral formulations, but savings may accrue through reduced hospitalization and improved adherence.

2. What are the main side effects associated with Aripiprazole Lauroxil?
Common side effects include akathisia, anxiety, insomnia, and headache. It has a lower risk of weight gain and metabolic issues than some other LAIs.

3. Are there any approved indications beyond schizophrenia?
Yes. In 2022, the FDA approved Aripiprazole Lauroxil for maintenance treatment of bipolar I disorder in adults.

4. How does reimbursement landscape affect sales?
Reimbursement policies favor LAIs with proven adherence benefits. Insurance coverage differences across regions impact patient access and, subsequently, revenue.

5. What differentiates Aripiprazole Lauroxil at market entry?
It offers a once-monthly injection with a potentially better side-effect profile, appealing to patients and providers seeking long-acting options with fewer metabolic concerns.

---

References

[1] IQVIA. (2022). Pharmaceutical market data.
[2] U.S. Food and Drug Administration. (2017). FDA approval letter for Aripiprazole Lauroxil.
[3] American Psychiatric Association. (2019). Practice guideline for the treatment of schizophrenia.
[4] EvaluatePharma. (2023). World market reports on antipsychotics.
[5] FDA. (2022). Approval of Aripiprazole Lauroxil for bipolar disorder.